AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, M.
Related Collections
Right arrow HIV/AIDS
Right arrow Prevention
Right arrow Lesbian/Gay/Bisexual/Transgender Persons
August 2003, Vol 93, No. 8 | American Journal of Public Health 1200
© 2003 American Public Health Association

LETTER

PREEMPTIVE USE OF ANTIRETROVIRAL DRUGS TO PREVENT SEXUAL TRANSMISSION OF HIV TO HIGH-RISK UNINFECTED MSM

Michael Gross, PhD

The author is the Journal’s associate editor for HIV/AIDS and lesbian-gay-bisexual-transgender health.

Correspondence: Requests for reprints should be sent to Michael Gross, PhD, 1601 18th St NW, #716, Washington DC 20009 (e-mail: m144@earthlink.net).

Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

In the June 2003 issue of the Journal, I posed the rhetorical question of why clinical trials of "pre-exposure prophylaxis" against sexual transmission were being planned for populations in developing countries, but not for men who have sex with men (MSM) who are at high risk of contracting HIV in the United States.1 As that issue of the Journal was in press, the Centers for Disease Control and Prevention (CDC) published plans to support a randomized, placebo-controlled trial of the extended safety and preliminary efficacy of once-daily oral administration of the antiretroviral drug tenofovir disoproxil fumarate (Viread) among high-risk MSM.2

. . . [Full Text]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Public Health Association